News

Celtaxsys has obtained financing for a Phase 3 clinical trial of acebilustat as a treatment for cystic fibrosis. Acebilustat inhibits an enzyme that takes part in the production of a substance called leukotriene B4 (LTB4) that promotes an immune response known as inflammation. Scientists believe LTB4 plays a key role…

A possible inhalable treatment for antibiotic-resistant bacterial infections in people with cystic fibrosis due to Pseudomonas aeruginosa now has a U.S. patent and is being readied for a first clinical trial, Novoclem Therapeutics announced. The patent (No. 9,850,322) was issued to the University of North Carolina (UNC) at Chapel Hill where the…

The most influential cystic fibrosis advocacy groups in the United States and Europe have endorsed the idea of a Phase 1 clinical trial to test a triple-combo therapy that Proteostasis Therapeutics has developed, the company announced. Proteostatis said the endorsements came from the Cystic Fibrosis Foundation’s and European CF Society’s clinical…

Galapagos is advancing its development of a range of cystic fibrosis (CF) treatments intended for use in combinations — either with already approved CF therapies or with its own compounds — the Belgian biotech company announced. Phase 2 trials Among the advances is completion of a Phase 2 trial…

Researchers in Canada found new blood biomarkers that can more accurately detect cystic fibrosis (CF) in newborns than standard screening methods — a discovery that could lead to improvements in early identification of this disease. The study, “Metabolic Signatures of Cystic Fibrosis Identified in Dried Blood Spots for Newborn Screening Without…

Synspira received an award of up to $3 million from the Cystic Fibrosis Foundation to advance the clinical development of its lead candidate, SNSP113, for the treatment of pulmonary complications in cystic fibrosis (CF). Synspira is a company developing a…

A number of cystic fibrosis discoveries, therapy advances and other developments were reported by Cystic Fibrosis News Today during 2017. Now that the year is over, it’s time to review the articles that appealed most to our readers. Here are the 10 most-read articles of 2017, with a brief description of what…

When two channels that are supposed to move chloride and sodium ions out of cells in the lungs fail to function properly, it leads to the mucus buildup seen in cystic fibrosis. Japanese researchers have discovered that the channel dysfunctions also reduce the amount of zinc ions going into the…

The overall rate at which women with cystic fibrosis are becoming pregnant dropped slightly in recent years — coinciding with the introduction of CFTR modulators and the clinical trials that led to their approval as CF therapies — but appears to be rising again to pre-trial levels, a study reports.

Pseudomonas aeruginosa is a bacteria that commonly infects cystic fibrosis patients. Now, researchers have designed a synthetic peptide that blocks the ability of these bacteria to cause disease. This discovery might be crucial in fighting infectious diseases and preventing bacteria from becoming resistant to nearly all the antibiotic drug options available.